Key highlights

  • CSL (ASX:CSL) expects FY27 revenue in line with the prior year and said it intends to spend about US$1.5 billion expanding US plasma manufacturing.
  • Ramsay Health Care (ASX:RHC) expects Ramsay Funding Group EBIT growth and margin improvement in FY27 and has a Ramsay Santé separation vote in November.
  • Sigma Healthcare (ASX:SIG) is targeting $100 million of annual synergies by FY29 and expects its store network to return to growth in FY27.

Healthcare companies combine long investment cycles with demand that is relatively stable, but their results can still be affected by regulation, competition and one-off items. This article reviews the forward-looking statements of CSL Limited (ASX:CSL), Ramsay Health Care Limited (ASX:RHC) and Sigma Healthcare Limited (ASX:SIG). They cover plasma therapies and vaccines, hospitals and pharmacy distribution and retail.

The theme is the future trajectory of each business, using the outlook, guidance and strategic plans in their FY26 releases.

CSL Limited (ASX:CSL)

CSL described FY26 as a reset year. Revenue was US$15.8 billion, underlying NPATA was US$3.1 billion, and a net loss of US$2.6 billion was recorded after pre-tax impairments of US$7.1 billion and restructuring costs of US$799 million. The final dividend of US$1.62 per share was maintained and the buy-back continued.

For FY27, CSL expects revenue in line with the prior year and underlying NPAT growth. CSL Behring expects mid-single-digit revenue growth, with immunoglobulin growth at mid-to-high single digits, CSL Seqirus expects low single-digit revenue growth, and CSL Vifor expects revenue to decline by about 25% because of generic competition in iron products. The company achieved about US$176 million of cost savings from its transformation program and plans to spend about US$1.5 billion expanding US plasma manufacturing.

Ramsay Health Care Limited (ASX:RHC)

Ramsay reported underlying EBIT of A$1,162.2 million, up 11.5%, underlying NPAT of A$364.1 million, up 19.3%, and a full-year dividend of 91.0 cents. Australian underlying EBIT rose 11.2%, and UK hospital EBIT rose 10.3% despite an 8% decline in NHS activity.

Its outlook includes the completion of the National Capital Private Hospital acquisition, expected by 1 September 2026, and an expectation that Ramsay Funding Group will report EBIT growth and margin improvement in FY27. A vote on the separation of Ramsay Santé is scheduled for November, and the release describes a discontinued business effect on first-half and FY27 results.

Sigma Healthcare Limited (ASX:SIG)

Sigma’s first full year after its merger with Chemist Warehouse Group delivered revenue of $10.8 billion, normalised EBIT of $1,090.0 million, up 20.6%, and normalised NPAT of $732.3 million, up 22.3%. Net debt was $663 million and integration synergies of $32.6 million were delivered.

Looking ahead, the company expects its store network to return to growth in FY27 with a pipeline of new stores, with some expected to open by the end of calendar 2026, and said it will consolidate distribution centre operations in South Australia in the first quarter of FY27. It targets $100 million of annual synergies by FY29 and noted that it is cycling elevated early-period sales growth.

General risks to keep in mind

Healthcare companies are exposed to regulation, reimbursement and funding settings, the timing of generic competition and clinical or product developments. Hospital operators depend on activity levels, government funding indexation and labour availability. Pharmacy and distribution businesses are affected by medicine demand, supplier terms and integration of acquired businesses. Large manufacturing investments require regulatory approvals and take time to contribute to earnings, and impairments can arise when commercial assumptions change.

What investors might be watching

  • CSL’s progress against its FY27 revenue and NPAT expectations, particularly in CSL Behring and the decline at CSL Vifor.
  • Execution of CSL’s US plasma manufacturing expansion and its transformation savings.
  • The outcome of the Ramsay Santé separation vote in November and completion of the National Capital Private Hospital acquisition.
  • Sigma’s store openings, distribution centre consolidation and synergy delivery.
  • Government funding and policy settings for hospitals, pharmacies and medicines.

What the next year could show

CSL, Ramsay and Sigma each pair FY26 results with specific forward steps: plasma manufacturing and a revenue outlook, a separation vote and an acquisition, and a store rollout with synergy targets. Their next reports will show how those steps progress.